Barclays’s Medicines Co MDCO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-22,400
| Closed | -$1.9M | – | 6741 |
|
|
2019
Q4 | $1.9M | Buy |
22,400
+14,800
| +195% | +$987K | ﹤0.01% | 3055 |
|
|
2019
Q3 | $380K | Buy |
7,600
+3,000
| +65% | +$120K | ﹤0.01% | 4466 |
|
|
2019
Q2 | $168K | Sell |
4,600
-78,500
| -94% | -$2.56M | ﹤0.01% | 5270 |
|
|
2019
Q1 | $2.32M | Buy |
83,100
+76,400
| +1,140% | +$1.8M | ﹤0.01% | 2403 |
|
|
2018
Q4 | $128K | Buy |
+6,700
| New | +$156K | ﹤0.01% | 4885 |
|
|
2018
Q2 | – | Sell |
-500
| Closed | -$16K | – | 7487 |
|
|
2018
Q1 | $16K | Sell |
500
-48,700
| -99% | -$1.52M | ﹤0.01% | 6517 |
|
|
2017
Q4 | $1.34M | Sell |
49,200
-36,000
| -42% | -$1.11M | ﹤0.01% | 2817 |
|
|
2017
Q3 | $3.16M | Buy |
85,200
+36,000
| +73% | +$1.33M | ﹤0.01% | 1906 |
|
|
2017
Q2 | $1.87M | Sell |
49,200
-161,900
| -77% | -$7.21M | ﹤0.01% | 2319 |
|
|
2017
Q1 | $10.3M | Buy |
211,100
+210,300
| +26,288% | +$9.59M | 0.01% | 855 |
|
|
2016
Q4 | $27K | Buy |
+800
| New | +$28.4K | ﹤0.01% | 5489 |
|
|
2016
Q1 | – | Sell |
-64,900
| Closed | -$2.4M | – | 6588 |
|
|
2015
Q4 | $2.4M | Buy |
64,900
+13,000
| +25% | +$491K | ﹤0.01% | 1875 |
|
|
2015
Q3 | $1.92M | Buy |
+51,900
| New | +$1.82M | ﹤0.01% | 2164 |
|
|
2015
Q2 | – | Sell |
-50,000
| Closed | -$1.4M | – | 7316 |
|
|
2015
Q1 | $1.4M | Buy |
+50,000
| New | +$1.4M | ﹤0.01% | 2654 |
|
|
2014
Q4 | – | Sell |
-25,000
| Closed | -$550K | – | 7750 |
|
|
2014
Q3 | $550K | Hold |
25,000
| – | – | ﹤0.01% | 3871 |
|
|
2014
Q2 | $725K | Buy |
+25,000
| New | +$668K | ﹤0.01% | 3635 |
|
|
2013
Q4 | – | Sell |
-13,100
| Closed | -$432K | – | 7773 |
|
|
2013
Q3 | $432K | Buy |
+13,100
| New | +$417K | ﹤0.01% | 4274 |
|
Other funds holding MDCO
Barclays's MDCO Position: Q1 2020 in Review
Barclays sold out of Medicines Co (MDCO) in Q1 2020, closing a stake of 325,106 shares — an estimated $27.6M sold.
Barclays first reported a position in MDCO in Q2 2013 and held it in 27 quarters. The position peaked at $27.6M in Q4 2019. 1 fund tracked by Wall St. Rank holds MDCO as of Q1 2020.
- Barclays reported no remaining Medicines Co position as of Q1 2020 after selling out during the quarter.
- Barclays sold 325,106 Medicines Co shares in Q1 2020, an estimated $27.6M.
- Barclays first reported a position in Medicines Co in Q2 2013 and held it in 27 quarters.
- Barclays's Medicines Co position peaked at $27.6M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Medicines Co as of Q1 2020.
Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.